Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918978 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
A Phase 2 study, sponsored by argenx.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT05918978 is a Phase 2 study that was terminated before completion, run by argenx. The registered enrollment target is 33 participants.
The verdict
NCT05918978, a Phase 2 study, was terminated before completion, sponsored by argenx.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
Interventions
- DRUG Efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918978
The ClinicalTrials.gov registry entry for NCT05918978 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efgartigimod is the first listed.
NCT05918978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05918978 about?
NCT05918978 is a clinical study titled "Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS". The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
What is the current status of trial NCT05918978?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-06-20. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT05918978?
The interventions under investigation include: Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT05918978?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.